Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1,571 MXN
Change Today 0.00 / 0.00%
Volume 0.0
NVSN On Other Exchanges
Symbol
Exchange
Xetra
New York
OTC US
Mexico
SIX Swiss Ex
SIX Swiss Ex
Frankfurt
As of 4:09 PM 06/24/15 All times are local (Market data is delayed by at least 15 minutes).

novartis ag-sponsored adr (NVSN) Snapshot

Open
$1,571
Previous Close
$1,571
Day High
$1,571
Day Low
$1,571
52 Week High
04/23/15 - $1,619
52 Week Low
08/7/14 - $1,134
Market Cap
4.2T
Average Volume 10 Days
626.2
EPS TTM
--
Shares Outstanding
2.7B
EX-Date
03/2/15
P/E TM
--
Dividend
$2.56
Dividend Yield
2.55%
Current Stock Chart for NOVARTIS AG-SPONSORED ADR (NVSN)

novartis ag-sponsored adr (NVSN) Related Businessweek News

View More BusinessWeek News

novartis ag-sponsored adr (NVSN) Details

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. The company’s Alcon division provides various eye care products, including surgical, ophthalmic pharmaceuticals, and vision care products; ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye; over-the-counter medicines for the eye; and contact lenses and lens care products. Its Sandoz division offers generic pharmaceuticals comprising active ingredients and finished dosage forms of pharmaceuticals; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or biotechnology-based products; and cytotoxic products for the hospital market, as well as biotech manufacturing services to other companies. The company distributes its OTC products through various channels, such as pharmacies, food, drug, and mass retail outlets. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.

120,000 Employees
Last Reported Date: 04/23/15
Founded in 1895

novartis ag-sponsored adr (NVSN) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: SFr.6.1M
Chief Financial Officer
Total Annual Compensation: SFr.2.6M
President of Institutes for Biomedical Resear...
Total Annual Compensation: $3.0M
Global Head of Novartis Business Services and...
Total Annual Compensation: SFr.1.2M
Division Head of Novartis Pharmaceuticals
Total Annual Compensation: $3.9M
Compensation as of Fiscal Year 2014.

novartis ag-sponsored adr (NVSN) Key Developments

Sandoz Launches Three New Generic Drugs in Japan

Sandoz launched three new generic drugs, clopidogrel, tacrolimus and pitavastatin, in Japan. Clopidogrel, a generic version of Sanofi's Plavix, is used for suppression of recurrence of ischemic cerebrovascular disorder. Tacrolimus, a generic version of Astellas's PROGRAF, is used among others to prevent organ transplant rejection (kidney, liver, heart, lung, pancreas, small intestine). Pitavastatin, a generic version of Kowa's LIVALO, is used for lowering cholesterol. "We are pleased to introduce three new important generic medicines in Japan.

Class Action Alleges Novartis Gleevec Patent Infringement Suit a Sham

A class-action lawsuit filed against Novartis alleges that the pharma company’s patent infringement suit against Sun Pharma was a sham, and seeks a permanent injunction to prevent Novartis or Sun from enforcing the terms of a settlement agreement that, barring relief, will delay the launch of generic Gleevec for months. According to Hagens Berman, the suit marks the first time purchasers of prescription drugs have sought injunctive relief to try to prevent antitrust overcharges or damages stemming from delayed launch of generic drugs. The lawsuit, filed June 22, 2015 in the U.S. District Court for the district of Massachusetts, seeks to prevent Novartis’ unlawful delay of generic Gleevec (imatinib mesylate), an FDA-approved prescription drug that radically improves the lives of the thousands of patients suffering chronic myeloid leukemia, a cancer of the blood and bone marrow. The drug’s compound patent expires on July 4, 2015, but Novartis unlawfully barred generic maker Sun Pharma from releasing its generic version of Gleevec for at least an additional seven months. Two generic versions of the drug have already been tentatively approved by the FDA. The suit names two end payers as plaintiffs and has been filed on behalf of a class of all purchasers of Gleevec.

Novartis Announces Long-Term Safety and Efficacy Results from the Pivotal Phase III Response Study Evaluating Jakavi

Novartis announced long-term safety and efficacy results from the pivotal Phase III RESPONSE study evaluating Jakavi (ruxolitinib) for the treatment of patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea. A preplanned analysis of the study at 18 months demonstrated that 80% of patients with inadequately controlled PV treated with Jakavi experienced a durable response of sustaining hematocrit less than 45% without the use of phlebotomy and reducing spleen size, two key measures of disease control, for at least one year. Findings were presented at the 20th Congress of the European Hematology Association (EHA) in Vienna, Austria. PV is a rare and incurable blood cancer associated with an overproduction of blood cells that can cause serious cardiovascular complications, such as blood clots, stroke and heart attack. Approximately 25% of patients with PV develop resistance (inadequate response) to or intolerance of hydroxyurea and are considered to have inadequately controlled disease[2]. This is typically defined as hematocrit levels greater than 45%, elevated white blood cell count and/or platelet count, and may be accompanied by debilitating symptoms and/or an enlarged spleen. In the Phase III study, 83% of patients with PV randomized to Jakavi were still receiving treatment at 18 months (median exposure of 111 weeks) compared to 0 patients on the best available treatment arm. Results also show that Jakavi-treated patients who achieved hematocrit control without phlebotomy had an 89% probability of maintaining their response for 18 months from the time of their initial response and all patients who had an initial spleen response maintained their reduction in spleen size. Of the patients on the Jakavi arm at week 32, 90% of patients did not have a phlebotomy between weeks 32 and 80. In addition, patients treated with Jakavi who achieved complete hematologic remission at week 32 had a 69% probability of maintaining their response for at least 18 months from the time of their initial response. A separate analysis of the study at 18 months demonstrated treatment with Jakavi also led to sustained control of white blood cell and platelet levels, important PV hematologic parameters, with the large reductions for patients with the most elevated values at baseline.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVSN:MM $1,570.80 MXN 0.00

NVSN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $117.11 USD +1.66
Johnson & Johnson $98.20 USD +0.52
Nestle SA SFr.67.85 CHF -1.10
Pfizer Inc $33.46 USD -0.135
Roche Holding AG SFr.263.30 CHF -0.10
View Industry Companies
 

Industry Analysis

NVSN

Industry Average

Valuation NVSN Industry Range
Price/Earnings 23.4x
Price/Sales 4.6x
Price/Book 3.2x
Price/Cash Flow 13.2x
TEV/Sales 4.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-SPONSORED ADR, please visit www.novartis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.